GSK PLC 20 December 2024 GSK plc Block listing Application Application has been made to the Financial Conduct Authority and the London Stock Exchange plc for a total of 700,000...
GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secon ...
GSK PLC 20 December 2024 Issued: 20 December 2024, London UK GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer · ...
GSK PLC on Monday reported a triple dose of good news with positive regulatory updates on two leading cancer drugs. ...
GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer · ...
GSK PLC 16 December 2024 Issued: 16 December 2024, London UK GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority Medicines (PRIME) Designation in relapsed...
GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary...
GSK PLC 12 December 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -13.5 | -1.01237345332 | 1333.5 | 1345 | 1301 | 7164498 | 1327.32834751 | DE |
4 | -5 | -0.377358490566 | 1325 | 1398 | 1301 | 7683613 | 1343.79072631 | DE |
12 | -205 | -13.4426229508 | 1525 | 1559.5 | 1282.5 | 8539786 | 1396.01436524 | DE |
26 | -299.5 | -18.4933621488 | 1619.5 | 1678 | 1282.5 | 7800893 | 1480.97270879 | DE |
52 | -125.8 | -8.70106515424 | 1445.8 | 1820 | 1282.5 | 7852701 | 1560.11997956 | DE |
156 | -265.8 | -16.7612561483 | 1585.8 | 1824.4 | 1282.5 | 8616204 | 1526.96305751 | DE |
260 | -489.6 | -27.0557029178 | 1809.6 | 1857 | 1190.8 | 8795347 | 1506.26630683 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約